Jiangsu GDK Biotechnology Co Ltd Total Liabilities
Jiangsu GDK Biotechnology Co Ltd total liabilities. Based on the latest financial reports, Jiangsu GDK Biotechnology Co Ltd (688670) has total liabilities worth CN¥279.22 Million CNY (≈ $40.86 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Jiangsu GDK Biotechnology Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jiangsu GDK Biotechnology Co Ltd (2017–2025)
Total liabilities of Jiangsu GDK Biotechnology Co Ltd from 2017 to 2025. This chart illustrates how Jiangsu GDK Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Jiangsu GDK Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu GDK Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kaltura Inc
NASDAQ:KLTR
|
USA | $167.13 Million |
|
Cantabil Retail India Limited
NSE:CANTABIL
|
India | Rs-4.78 Billion |
|
Launchpad Cadenza Acquisition Corp I Class A Ordinary Share
NASDAQ:LPCV
|
USA | $11.06 Million |
|
Batavia Prosperindo Int
JK:BPII
|
Indonesia | Rp3.40 Trillion |
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
USA | $32.46 Million |
|
Sakar Healthcare Limited
NSE:SAKAR
|
India | Rs-3.24 Billion |
|
Chongqing Wanli New Energy Co Ltd
SHG:600847
|
China | CN¥45.97 Million |
|
TYC Brother Industrial Co Ltd
TW:1522
|
Taiwan | NT$27.37 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Jiangsu GDK Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Jiangsu GDK Biotechnology Co Ltd total assets.
Liquidity & Leverage Metrics
Jiangsu GDK Biotechnology Co Ltd Total Liabilities Ratios Explained
Jiangsu GDK Biotechnology Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu GDK Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu GDK Biotechnology Co Ltd (2017–2025)
The table below shows the annual total liabilities of Jiangsu GDK Biotechnology Co Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥319.50 Million ≈ $46.75 Million |
+25.13% |
| 2024-12-31 | CN¥255.33 Million ≈ $37.36 Million |
-1.99% |
| 2023-12-31 | CN¥260.52 Million ≈ $38.12 Million |
-29.03% |
| 2022-12-31 | CN¥367.11 Million ≈ $53.72 Million |
+25.24% |
| 2021-12-31 | CN¥293.12 Million ≈ $42.89 Million |
-45.26% |
| 2020-12-31 | CN¥535.47 Million ≈ $78.36 Million |
+5.89% |
| 2019-12-31 | CN¥505.68 Million ≈ $74.00 Million |
+26.19% |
| 2018-12-31 | CN¥400.73 Million ≈ $58.64 Million |
+11.50% |
| 2017-12-31 | CN¥359.39 Million ≈ $52.59 Million |
-- |
About Jiangsu GDK Biotechnology Co Ltd
Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines. The company human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. Jiangsu Gdk Biological Technology Co., Ltd was founded in 2008… Read more